Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2003-05-21
2009-12-29
Mondesi, Robert B (Department: 1645)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S455000, C435S320100, C435S325000, C514S04400A, C424S093100, C536S023700, C536S023400
Reexamination Certificate
active
07638333
ABSTRACT:
Using the nontoxic PA protein fromB. anthracis, a method and composition for use in inducing an immune response which is protective against anthrax in subjects is described.
REFERENCES:
patent: 5591631 (1997-01-01), Leppla et al.
patent: 5677274 (1997-10-01), Leppla et al.
patent: 6592872 (2003-07-01), Klimpel et al.
patent: 6770479 (2004-08-01), Lee et al.
patent: 2002/0034512 (2002-03-01), Ivins et al.
patent: 2002/0137058 (2002-09-01), Mirkin et al.
patent: 94/18332 (1994-08-01), None
patent: WO 95/07994 (1995-03-01), None
patent: WO 96/17067 (1996-06-01), None
patent: WO 96/37616 (1996-11-01), None
patent: WO 98/08952 (1998-03-01), None
Singh, Y et al, The Journal of Biological Chemistry, vol. 266(23), pp. 15493-15497, Aug. 15, 1991, The Carboxyl-terminal End of Protective antigen is required for receptor binding and Anthrax toxin activity.
Iacono-Connors, L et al, Infection and Immunity, vol. 59(6), pp. 1961-1965, Jun. 1991, Protection against Anthrax with recombinant virus expressed Protective Antigen in Experimental Animals.
Pushko, Peter et al Virology, vol. 239, pates 389-401, 1997, Replicon-Helper Systems from attenuated Venezuelan Equine Encephalitis Virus:Expression of Heterologous Genes in Vitro and Immunization against Heterologous Pathogens in Vivo.
Lee, John S e tal, Vanezuelan Equine Encephalitis Virus-Vectored Vaccines Protect Mice against Anthrax Spore Challenge, Infection and Immunity Mar. 2003, vol. 71(3), pp. 1491-1496.
International Search Report issued Aug. 2, 2000 in related PCT application PCT/US99/15568 (11 pages).
Clayton et al., “Protective Vaccination with a Recombinant Fragment of Clostridium botulinum Neurotoxin Serotype A Expressed from a Synthetic Gene inE. coli”, Infection and Immunity, Jul. 1995, vol. 63, No. 7, pp. 2738-2742.
Byrne, et al., “Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain fromPichia pastorisas a Recombinant Vaccine Candidate”, Infection and Immunity, Oct. 1998, vol. 66, No. 10, pp. 4817-4822.
Pushko, et al., “Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes in Vitro and Immunization against Heterologous Pathogens in Vivo,” Virology:239, pp. 389-401 (1997).
Bavari, et al., “Engineered Bacterial Superantigen Vaccines”, Vaccines 96, 1996, pp. 135-141.
Welkos et al., “Sequence and analysis of the DNA encoding protective antigen ofBacillus anthracis”, Gene, 69, 1988, pp. 287-300.
Iocono-Connors et al., “Protection against Anthrax with Recombinant Virus-Expressed Protective Antigen in Experimental Animals”, Infection and Immunity, Jun. 1991, pp. 1961-1965.
Singh, et al., “A Deleted Variant ofBacillus antracixProtective Antigen is Non-toxic and Blocks Anthrax Toxin Action in Vivo”, The Journal of Biological Chemistry, vol. 264, No. 32, pp. 19101-19107, Nov. 15, 1989.
Ivins and Welkos, “Cloning and Expression of theBacillus anthracisProtective Antigen Gene inBacillus subtilis”, Infectin and Immunity, vol. 54, No. 2, pp. 537-542 (Nov. 1986).
Orkin et al., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, Dec. 1995, pp. 1-41.
Chattergoon et al, FASEB, “Genetic Immunization: A New Era in Vaccines and Immune Therapeutics,” May 1997, 11, pp. 753-763.
McDonnell et al., The New England Journal of Medicine, “Molecular Medicine DNA Vaccines”, Jan. 1996, vol. 334, No. 1, pp. 42-45.
Ledley, Human Gene Therapy, “Clinical Considerations in the Design of Protocols for Somatic Gene Therapy,” 1991, 2:77-83.
Zinkernagel, Fundamental Immunology, “Immunity to Viruses”, Chap. 34, 3rd Ed., pp. 1211-1250.
Lee John S.
Parker Michael D.
Pushko Peter
Smith Jonathan F.
Welkos Susan L.
Arwine Elizabeth
Mondesi Robert B
Portner Ginny
The United States of America as represented by the Secretary of
LandOfFree
Anthrax vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anthrax vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anthrax vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4133665